Cancer and Metastasis Reviews

, 26:503 | Cite as

Lipoxygenase metabolism: roles in tumor progression and survival

  • Graham P. Pidgeon
  • Joanne Lysaght
  • Sriram Krishnamoorthy
  • John V. Reynolds
  • Ken O’Byrne
  • Daotai Nie
  • Kenneth V. Honn


The metabolism of arachidonic acid through lipoxygenase pathways leads to the generation of various biologically active eicosanoids. The expression of these enzymes vary throughout the progression of various cancers, and thereby they have been shown to regulate aspects of tumor development. Substantial evidence supports a functional role for lipoxygenase-catalyzed arachidonic and linoleic acid metabolism in cancer development. Pharmacologic and natural inhibitors of lipoxygenases have been shown to suppress carcinogenesis and tumor growth in a number of experimental models. Signaling of hydro[peroxy]fatty acids following arachidonic or linoleic acid metabolism potentially effect diverse biological phenomenon regulating processes such as cell growth, cell survival, angiogenesis, cell invasion, metastatic potential and immunomodulation. However, the effects of distinct LOX isoforms differ considerably with respect to their effects on both the individual mechanisms described and the tumor being examined. 5-LOX and platelet type 12-LOX are generally considered pro-carcinogenic, with the role of 15-LOX-1 remaining controversial, while 15-LOX-2 suppresses carcinogenesis. In this review, we focus on the molecular mechanisms regulated by LOX metabolism in some of the major cancers. We discuss the effects of LOXs on tumor cell proliferation, their roles in cell cycle control and cell death induction, effects on angiogenesis, migration and the immune response, as well as the signal transduction pathways involved in these processes. Understanding the molecular mechanisms underlying the anti-tumor effect of specific, or general, LOX inhibitors may lead to the design of biologically and pharmacologically targeted therapeutic strategies inhibiting LOX isoforms and/or their biologically active metabolites, that may ultimately prove useful in the treatment of cancer, either alone or in combination with conventional therapies.


Lipoxygenase Tumor survival Apoptosis Angiogenesis Immune suppression 


  1. 1.
    Cuendet, M., & Pezzuto, J. M. (2000). The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabolism and Drug Interactions, 17(1–), 109–57.PubMedGoogle Scholar
  2. 2.
    Klurfeld, D. M., & Bull, A. W. (1997). Fatty acids and colon cancer in experimental models. American Journal of Clinical Nutrition, 66(6 Suppl), 1530S–538S.PubMedGoogle Scholar
  3. 3.
    Furstenberger, G., Krieg, P., Muller-Decker, K., & Habenicht, A. J. (2006). What are cyclooxygenases and lipoxygenases doing in the driver’s seat of carcinogenesis? International Journal of Cancer, 119(10), 247–54.CrossRefGoogle Scholar
  4. 4.
    Krysan, K., Reckamp, K. L., Sharma, S., & Dubinett, S. M. (2006). The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents in Medical Chemistry, 6(3), 209–20.CrossRefGoogle Scholar
  5. 5.
    Nie, D. (2007). Cyclooxygenases and lipoxygenases in prostate and breast cancers. Frontiers in Bioscience, 12, 1574–585.PubMedCrossRefGoogle Scholar
  6. 6.
    Funk, C. D. (2001). Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science, 294(5548), 1871–875.PubMedCrossRefGoogle Scholar
  7. 7.
    Krieg, P., Heidt, M., Siebert, M., Kinzig, A., Marks, F., & Furstenberger, G. (2002). Epidermis-type lipoxygenases. Advances in Experimental Medicine and Biology, 507, 165–70.PubMedGoogle Scholar
  8. 8.
    Yu, Z., Schneider, C., Boeglin, W. E., Marnett, L. J., & Brash, A. R. (2003). The lipoxygenase gene ALOXE3 implicated in skin differentiation encodes a hydroperoxide isomerase. Proceedings of the National Academy of Sciences of the United States of America, 100(16), 9162–167.PubMedCrossRefGoogle Scholar
  9. 9.
    Funk, C. D. (1993). Molecular biology in the eicosanoid field. Progress in Nucleic Acid Research and Molecular Biology, 45, 67–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Fabre, J. E., Goulet, J. L., Riche, E., et al. (2002). Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. Journal of Clinical Investigation, 109(10), 1373–380.PubMedGoogle Scholar
  11. 11.
    Kuhn, H., Walther, M., & Kuban, R. J. (2002). Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins and Other Lipid Mediators, 68–9, 263–90.CrossRefGoogle Scholar
  12. 12.
    Conrad, D. J. (1999). The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function. Clinical Reviews in Allergy and Immunology, 17(1–), 71–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Brash, A. R., Boeglin, W. E., & Chang, M. S. (1997). Discovery of a second 15S-lipoxygenase in humans. Proceedings of the National Academy of Sciences of the United States of America, 94(12), 6148–152.PubMedCrossRefGoogle Scholar
  14. 14.
    Shureiqi, I., & Lippman, S. M. (2001). Lipoxygenase modulation to reverse carcinogenesis. Cancer Research, 61(17), 6307–312.PubMedGoogle Scholar
  15. 15.
    van Leyen, K., Duvoisin, R. M., Engelhardt, H., & Wiedmann, M. (1998). A function for lipoxygenase in programmed organelle degradation. Nature, 395(6700), 392–95.PubMedCrossRefGoogle Scholar
  16. 16.
    Shureiqi, I., Chen, D., Lotan, R., et al. (2000). 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Research, 60(24), 6846–850.PubMedGoogle Scholar
  17. 17.
    Norel, X., & Brink, C. (2004). The quest for new cysteinyl-leukotriene and lipoxin receptors: Recent clues. Pharmacology and Therapeutics, 103(1), 81–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Michalik, L., Desvergne, B., & Wahli, W. (2004). Peroxisome-proliferator-activated receptors and cancers: Complex stories. Naturalist Review. Cancer, 4(1), 61–0.CrossRefGoogle Scholar
  19. 19.
    Catalano, A., & Procopio, A. (2005). New aspects on the role of lipoxygenases in cancer progression. Histology and Histopathology, 20(3), 969–75.PubMedGoogle Scholar
  20. 20.
    Shureiqi, I., Wojno, K. J., Poore, J. A., et al. (1999). Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis, 20(10), 1985–995.PubMedCrossRefGoogle Scholar
  21. 21.
    Subbarayan, V., Xu, X. C., Kim, J., et al. (2005). Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia, 7(3), 280–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Gonzalez, A. L., Roberts, R. L., Massion, P. P., Olson, S. J., Shyr, Y., & Shappell, S. B. (2004). 15-Lipoxygenase-2 expression in benign and neoplastic lung: An immunohistochemical study and correlation with tumor grade and proliferation. Human Pathology, 35(7), 840–49.PubMedCrossRefGoogle Scholar
  23. 23.
    Shappell, S. B., Boeglin, W. E., Olson, S. J., Kasper, S., & Brash, A. R. (1999). 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. American Journal of Pathology, 155(1), 235–45.PubMedGoogle Scholar
  24. 24.
    Tang, D. G., Bhatia, B., Tang, S., & Schneider-Broussard, R. (2007). 15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins and Other Lipid Mediators, 82(1–), 135–46.PubMedCrossRefGoogle Scholar
  25. 25.
    Chen, X., Wang, S., Wu, N., et al. (2004). Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clinical Cancer Research, 10(19), 6703–709.PubMedCrossRefGoogle Scholar
  26. 26.
    Jiang, W. G., Douglas-Jones, A., & Mansel, R. E. (2003). Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids, 69(4), 275–81.CrossRefGoogle Scholar
  27. 27.
    Ohd, J. F., Nielsen, C. K., Campbell, J., Landberg, G., Lofberg, H., & Sjolander, A. (2003). Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology, 124(1), 57–0.PubMedCrossRefGoogle Scholar
  28. 28.
    Gupta, S., Srivastava, M., Ahmad, N., Sakamoto, K., Bostwick, D. G., & Mukhtar, H. (2001). Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer, 91(4), 737–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Gao, X., Grignon, D. J., Chbihi, T., et al. (1995). Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology, 46(2), 227–37.PubMedCrossRefGoogle Scholar
  30. 30.
    Kim, E., Rundhaug, J. E., Benavides, F., Yang, P., Newman, R. A., & Fischer, S. M. (2005). An antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis. Oncogene, 24(7), 1174–187.PubMedCrossRefGoogle Scholar
  31. 31.
    Muller, K., Siebert, M., Heidt, M., Marks, F., Krieg, P., & Furstenberger, G. (2002). Modulation of epidermal tumor development caused by targeted overexpression of epidermis-type 12S-lipoxygenase. Cancer Research, 62(16), 4610–616.PubMedGoogle Scholar
  32. 32.
    Jiang, W. G., Watkins, G., Douglas-Jones, A., & Mansel, R. E. (2006). Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids, 74(4), 235–45.CrossRefGoogle Scholar
  33. 33.
    Jiang, W. G., Douglas-Jones, A. G., & Mansel, R. E. (2006). Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids, 74(2), 125–34.CrossRefGoogle Scholar
  34. 34.
    Shureiqi, I., Wu, Y., Chen, D., et al. (2005). The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Research, 65(24), 11486–1492.PubMedCrossRefGoogle Scholar
  35. 35.
    Nithipatikom, K., Isbell, M. A., See, W. A., & Campbell, W. B. (2006). Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. Cancer Letters, 233(2), 219–25.PubMedCrossRefGoogle Scholar
  36. 36.
    Kelavkar, U. P., Cohen, C., Kamitani, H., Eling, T. E., & Badr, K. F. (2000). Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: Correlation with Gleason staging. Carcinogenesis, 21(10), 1777–787.PubMedCrossRefGoogle Scholar
  37. 37.
    Hong, S. H., Avis, I., Vos, M. D., Martinez, A., Treston, A. M., & Mulshine, J. L. (1999). Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Research, 59(9), 2223–228.PubMedGoogle Scholar
  38. 38.
    Nie, D., Krishnamoorthy, S., Jin, R., et al. (2006). Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. Journal of Biological Chemistry, 281(27), 18601–8609.PubMedCrossRefGoogle Scholar
  39. 39.
    Ye, Y. N., Wu, W. K., Shin, V. Y., & Cho, C. H. (2005). A mechanistic study of colon cancer growth promoted by cigarette smoke extract. European Journal of Pharmacology, 519(1–), 52–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Gately, S. (2000). The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer and Metastasis Reviews, 19(1–), 19–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Cao, Y., Pearman, A. T., Zimmerman, G. A., McIntyre, T. M., & Prescott, S. M. (2000). Intracellular unesterified arachidonic acid signals apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 97(21), 11280–1285.PubMedCrossRefGoogle Scholar
  42. 42.
    Cianchi, F., Cortesini, C., Magnelli, L., et al. (2006). Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Molecular Cancer Therapeutics, 5(11), 2716–726.PubMedCrossRefGoogle Scholar
  43. 43.
    Gregor, J. I., Kilian, M., Heukamp, I., et al. (2005). Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. Prostaglandins, Leukotrienes and Essential Fatty Acids, 73(2), 89–7.CrossRefGoogle Scholar
  44. 44.
    Teicher, B. A., Korbut, T. T., Menon, K., Holden, S. A., & Ara, G. (1994). Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemotherapy and Pharmacology, 33(6), 515–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Duffy, C. P., Elliott, C. J., O’Connor, R. A., et al. (1998). Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). European Journal of Cancer, 34(8), 1250–259.PubMedCrossRefGoogle Scholar
  46. 46.
    Soriano, A. F., Helfrich, B., Chan, D. C., Heasley, L. E., Bunn, P. A., Jr., & Chou, T. C. (1999). Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Research, 59(24), 6178–184.PubMedGoogle Scholar
  47. 47.
    Brash, A. R. (1999). Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. Journal of Biological Chemistry, 274(34), 23679–3682.PubMedCrossRefGoogle Scholar
  48. 48.
    Ihara, A., Wada, K., Yoneda, M., Fujisawa, N., Takahashi, H., & Nakajima, A. (2007). Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. Journal of Pharmacology Science, 103(1), 24–2.CrossRefGoogle Scholar
  49. 49.
    Ye, Y. N., Liu, E. S., Shin, V. Y., Wu, W. K., & Cho, C. H. (2004). The modulating role of nuclear factor-kappaB in the action of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. Journal of Pharmacology and Experimental Therapeutics, 311(1), 123–30.PubMedCrossRefGoogle Scholar
  50. 50.
    Ye, Y. N., Liu, E. S., Shin, V. Y., Wu, W. K., & Cho C. H. (2004). Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology, 203(1–), 179–88.PubMedCrossRefGoogle Scholar
  51. 51.
    Kandouz, M., Nie, D., Pidgeon, G. P., Krishnamoorthy, S., Maddipati, K. R., & Honn K. V. (2003). Platelet-type 12-lipoxygenase activates NF-kappaB in prostate cancer cells. Prostaglandins and Other Lipid Mediators, 71(3–), 189–04.PubMedCrossRefGoogle Scholar
  52. 52.
    Hsi, L. C., Wilson, L. C., & Eling, T. E. (2002). Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry, 277(43), 40549–0556.PubMedCrossRefGoogle Scholar
  53. 53.
    Hassan, S., & Carraway, R. E. (2006). Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. Regulatory Peptide, 133(1–), 105–14.CrossRefGoogle Scholar
  54. 54.
    Yoshinaga, M., Buchanan, F. G., & DuBois, R. N. (2004). 15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK 1/2 signaling in colon carcinoma cells. Prostaglandins and Other Lipid Mediators, 73(1–), 111–22.PubMedCrossRefGoogle Scholar
  55. 55.
    Ding, X. Z., Tong, W. G., & Adrian, T. E. (2001). 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. International Journal of Cancer, 94(5), 630–36.CrossRefGoogle Scholar
  56. 56.
    Sharma, G. D., Ottino, P., Bazan, N. G., & Bazan, H. E. (2005). Epidermal and hepatocyte growth factors, but not keratinocyte growth factor, modulate protein kinase Calpha translocation to the plasma membrane through 15(S)-hydroxyeicosatetraenoic acid synthesis. Journal of Biological Chemistry, 280(9), 7917–924.PubMedCrossRefGoogle Scholar
  57. 57.
    Nie, D., & Honn, K. V. (2002). Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cellular and Molecular Life Sciences, 59(5), 799–07.PubMedCrossRefGoogle Scholar
  58. 58.
    Szekeres, C. K., Tang, K., Trikha, M., & Honn, K. V. (2000). Eicosanoid activation of extracellular signal-regulated kinase1/2 in human epidermoid carcinoma cells. Journal of Biological Chemistry, 275(49), 38831–8841.PubMedCrossRefGoogle Scholar
  59. 59.
    Szekeres, C. K., Trikha, M., Nie, D., & Honn, K. V. (2000). Eicosanoid 12(S)-HETE activates phosphatidylinositol 3-kinase. Biochemical and Biophysical Research Communications, 275(2), 690–95.PubMedCrossRefGoogle Scholar
  60. 60.
    Tong, W. G., Ding, X. Z., & Adrian, T. E. (2002). The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochemical and Biophysical Research Communications, 296(4), 942–48.PubMedCrossRefGoogle Scholar
  61. 61.
    Hoque, A., Lippman, S. M., Wu, T. T., et al. (2005). Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: A potential target for prevention. Carcinogenesis, 26(4), 785–91.PubMedCrossRefGoogle Scholar
  62. 62.
    Leung, H. W., Yang, W. H., Lai, M. Y., Lin, C. J., & Lee, H. Z. (2007). Inhibition of 12-lipoxygenase during baicalein-induced human lung nonsmall carcinoma H460 cell apoptosis. Food and Chemical Toxicology, 45(3), 403–11.PubMedCrossRefGoogle Scholar
  63. 63.
    Pidgeon, G. P., Kandouz, M., Meram, A., & Honn, K. V. (2002). Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Research, 62(9), 2721–727.PubMedGoogle Scholar
  64. 64.
    Harbour, J. W., & Dean, D. C. (2000). Rb function in cell-cycle regulation and apoptosis. Nature Cell Biology, 2(4), E65’E67.PubMedCrossRefGoogle Scholar
  65. 65.
    Yu, M. K., Moos, P. J., Cassidy, P., Wade, M., & Fitzpatrick, F. A. (2004). Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: Modulation of selenoproteins by lipoxygenase enzymes. Journal of Biological Chemistry, 279(27), 28028–8035.PubMedCrossRefGoogle Scholar
  66. 66.
    Datta, S. R., Dudek, H., Tao, X., et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91(2), 231–41.PubMedCrossRefGoogle Scholar
  67. 67.
    Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. (1998). Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. Journal of Biological Chemistry, 273(45), 29864–9872.PubMedCrossRefGoogle Scholar
  68. 68.
    Sauter, E. R., Nesbit, M., Litwin, S., Klein-Szanto, A. J., Cheffetz, S., & Herlyn, M. (1999). Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Research, 59(19), 4876–881.PubMedGoogle Scholar
  69. 69.
    Catalano, A., Rodilossi, S., Caprari, P., Coppola, V., & Procopio, A. (2005). 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO Journal, 24(1), 170–79.PubMedCrossRefGoogle Scholar
  70. 70.
    Ou, D., Bonomi, P., Jao, W., Jadko, S., Harris, J. E., & Anderson, K. M. (2001). The mode of cell death in H-358 lung cancer cells cultured with inhibitors of 5-lipoxygenase or the free radical spin trap, NTBN. Cancer Letters, 166(2), 223–31.PubMedCrossRefGoogle Scholar
  71. 71.
    Folkman, J., & Klagsbrun, M. (1987). Angiogenic factors. Science, 235(4787), 442–47.PubMedCrossRefGoogle Scholar
  72. 72.
    Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nature Medicine, 6(4), 389–95.CrossRefGoogle Scholar
  73. 73.
    Bergers, G., & Benjamin L. E. (2003). Tumorigenesis and the angiogenic switch. Naturalist Review. Cancer, 3(6), 401–10.PubMedGoogle Scholar
  74. 74.
    Ferrara, N. (2002). VEGF and the quest for tumour angiogenesis factors. Naturalist Review. Cancer, 2(10), 795–03.CrossRefGoogle Scholar
  75. 75.
    Pages, G., & Pouyssegur, J. (2005). Transcriptional regulation of the Vascular Endothelial Growth Factor gene’a concert of activating factors. Cardiovascular Research, 65(3), 564–73.PubMedCrossRefGoogle Scholar
  76. 76.
    Rose, D. P., & Connolly, J. M. (2000). Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids. Nutrition and Cancer, 37(2), 119–27.PubMedCrossRefGoogle Scholar
  77. 77.
    Nie, D., Hillman, G. G., Geddes, T., et al. (1998). Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Research, 58(18), 4047–051.PubMedGoogle Scholar
  78. 78.
    Tang, D. G., Renaud, C., Stojakovic, S., Diglio, C. A., Porter, A., & Honn, K. V. (1995). 12(S)-HETE is a mitogenic factor for microvascular endothelial cells: Its potential role in angiogenesis. Biochemical and Biophysical Research Communications, 211(2), 462–68.PubMedCrossRefGoogle Scholar
  79. 79.
    Nie, D., Tang, K., Diglio, C., & Honn, K. V. (2000). Eicosanoid regulation of angiogenesis: Role of endothelial arachidonate 12-lipoxygenase. Blood, 95(7), 2304–311.PubMedGoogle Scholar
  80. 80.
    Tang, D. G., Grossi, I. M., Chen, Y. Q., Diglio, C. A., & Honn, K. V. (1993). 12(S)-HETE promotes tumor-cell adhesion by increasing surface expression of alpha V beta 3 integrins on endothelial cells. International Journal of Cancer, 54(1), 102–11.CrossRefGoogle Scholar
  81. 81.
    Tang, D. G., Diglio, C. A., & Honn, K. V. (1993). 12(S)-HETE-induced microvascular endothelial cell retraction results from PKC-dependent rearrangement of cytoskeletal elements and alpha V beta 3 integrins. Prostaglandins, 45(3), 249–67.PubMedCrossRefGoogle Scholar
  82. 82.
    Honn, K. V., Grossi, I. M., Diglio, C. A., Wojtukiewicz, M., & Taylor, J. D. (1989). Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE-induced endothelial cell retraction. FASEB Journal, 3(11), 2285–293.PubMedGoogle Scholar
  83. 83.
    McCabe, N. P., Selman, S. H., & Jankun, J. (2006). Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase. Prostate, 66(7), 779–87.PubMedCrossRefGoogle Scholar
  84. 84.
    Harats, D., Ben-Shushan, D., Cohen, H., et al. (2005). Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoxygenase in the vascular wall under the control of murine preproendothelin-1 promoter. Cancer Letters, 229(1), 127–34.PubMedCrossRefGoogle Scholar
  85. 85.
    Bissell, M. J., Weaver, V. M., Lelievre, S. A., Wang, F., Petersen, O. W., & Schmeichel, K. L. (1999). Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Research, 59(7 Suppl), 1757–763s; discussion 63s–4s.Google Scholar
  86. 86.
    Giancotti, F. G., & Ruoslahti, E. (1999). Integrin signaling. Science, 285(5430), 1028–032.PubMedCrossRefGoogle Scholar
  87. 87.
    Howe, A., Aplin, A. E., Alahari, S. K., & Juliano, R. L. (1998). Integrin signaling and cell growth control. Current Opinion in Cell Biology, 10(2), 220–31.PubMedCrossRefGoogle Scholar
  88. 88.
    Clark, E. A., & Brugge, J. S. (1995). Integrins and signal transduction pathways: The road taken. Science, 268(5208), 233–39.PubMedCrossRefGoogle Scholar
  89. 89.
    Felsenfeld, D. P., Choquet, D., & Sheetz, M. P. (1996). Ligand binding regulates the directed movement of beta1 integrins on fibroblasts. Nature, 383(6599), 438–40.PubMedCrossRefGoogle Scholar
  90. 90.
    Gilmore, A. P., & Burridge, K. (1996). Molecular mechanisms for focal adhesion assembly through regulation of protein’protein interactions. Structure, 4(6), 647–51.PubMedCrossRefGoogle Scholar
  91. 91.
    Brassard, D. L., Maxwell, E., Malkowski, M., Nagabhushan, T. L. Kumar, C. C., & Armstrong, L. (1999). Integrin alpha(v)beta(3)-mediated activation of apoptosis. Experimental Cell Research, 251(1), 33–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Erdreich-Epstein, A., Shimada, H., Groshen, S., et al. (2000). Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Research, 60(3), 712–21.PubMedGoogle Scholar
  93. 93.
    Noti, J. D., & Johnson, A. K. (2001). Integrin alpha 5 beta 1 suppresses apoptosis triggered by serum starvation but not phorbol ester in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. International Journal of Oncology, 18(1), 195–01.PubMedGoogle Scholar
  94. 94.
    Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S., & Gladson, C. L. (1999). Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clinical Cancer Research, 5(6), 1587–594.PubMedGoogle Scholar
  95. 95.
    Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., & Downward, J. (1997). Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO Journal, 16(10), 2783–793.PubMedCrossRefGoogle Scholar
  96. 96.
    Dominguez-Jimenez, C., Diaz-Gonzalez, F., Gonzalez-Alvaro, I., Cesar, J. M., & Sanchez-Madrid, F. (1999). Prevention of alphaII(b)beta3 activation by non-steroidal antiinflammatory drugs. FEBS Letters, 446(2–), 318–22.PubMedCrossRefGoogle Scholar
  97. 97.
    Dormond, O., Bezzi, M., Mariotti, A., & Ruegg, C. (2002). Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. Journal of Biological Chemistry, 277(48), 45838–5846.PubMedCrossRefGoogle Scholar
  98. 98.
    Raso, E., Tovari, J., Toth, K., et al. (2001). Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells. Thrombosis and Haemostasis, 85(6), 1037–042.PubMedGoogle Scholar
  99. 99.
    Patricia, M. K., Kim, J. A., Harper, C. M., et al. (1999). Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(11), 2615–622.PubMedGoogle Scholar
  100. 100.
    Tang, K., Finley, R. L., Jr., Nie, D., & Honn, K. V. (2000). Identification of 12-lipoxygenase interaction with cellular proteins by yeast two-hybrid screening. Biochemistry, 39(12), 3185–191.PubMedCrossRefGoogle Scholar
  101. 101.
    Pidgeon, G. P., Tang, K., Cai, Y. L., Piasentin, E., & Honn, K. V. (2003). Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Research, 63(14), 4258–267.PubMedGoogle Scholar
  102. 102.
    Lewis, J. M., Cheresh, D. A., & Schwartz, M. A. (1996). Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. Journal of Cell Biology, 134(5), 1323–332.PubMedCrossRefGoogle Scholar
  103. 103.
    Tang, D. G., Diglio, C. A., Bazaz, R., & Honn, K. V. (1995). Transcriptional activation of endothelial cell integrin alpha v by protein kinase C activator 12(S)-HETE. Journal of Cell Science, 108(Pt 7), 2629–644.PubMedGoogle Scholar
  104. 104.
    Palmantier, R., Roberts, J. D., Glasgow, W. C., Eling, T., & Olden, K. (1996). Regulation of the adhesion of a human breast carcinoma cell line to type IV collagen and vitronectin: Roles for lipoxygenase and protein kinase C. Cancer Research, 56(9), 2206–212.PubMedGoogle Scholar
  105. 105.
    Paine, E., Palmantier, R., Akiyama, S. K., Olden, K., & Roberts, J. D. (2000). Arachidonic acid activates mitogen-activated protein (MAP) kinase-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway. Journal of Biological Chemistry, 275(15), 11284–1290.PubMedCrossRefGoogle Scholar
  106. 106.
    Palmantier, R., George, M. D., Akiyama, S. K., Wolber, F. M., Olden, K., & Roberts, J. D. (2001). Cis-polyunsaturated fatty acids stimulate beta1 integrin-mediated adhesion of human breast carcinoma cells to type IV collagen by activating protein kinases C-epsilon and -mu. Cancer Research, 61(6), 2445–452.PubMedGoogle Scholar
  107. 107.
    Nony, P. A., Kennett, S. B., Glasgow, W. C., Olden, K., & Roberts, J. D. (2005). 15S-Lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6, and p38 MAPK. Journal of Biological Chemistry, 280(36), 31413–1419.PubMedCrossRefGoogle Scholar
  108. 108.
    Taylor, P. M., Woodfield, R. J., Hodgkin, M. N., et al. (2002). Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene, 21(37), 5765–772.PubMedCrossRefGoogle Scholar
  109. 109.
    Fiorucci, S., Distrutti, E., Mencarelli, A., et al. (2003). Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte’endothelial adherence in response to aspirin. British Journal of Pharmacology, 139(7), 1351–359.PubMedCrossRefGoogle Scholar
  110. 110.
    Timar, J., Tovari, J., Raso, E., Meszaros, L., Bereczky, B., & Lapis, K. (2005). Platelet-mimicry of cancer cells: Epiphenomenon with clinical significance. Oncology, 69(3), 185–01.PubMedCrossRefGoogle Scholar
  111. 111.
    Nie, D., Nemeth, J., Qiao, Y., et al. (2003). Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clinical & Experimental Metastasis, 20(7), 657–63.CrossRefGoogle Scholar
  112. 112.
    Harizi, H., Juzan, M., Pitard, V., Moreau, J. F., & Gualde, N. (2002). Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. Journal of Immunology, 168(5), 2255–263.Google Scholar
  113. 113.
    Stolina, M., Sharma, S., Lin, Y., et al. (2000). Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. Journal of Immunology, 164(1), 361–70.Google Scholar
  114. 114.
    Legler, D. F., Krause, P., Scandella, E., Singer, E., & Groettrup, M. (2006). Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. Journal of Immunology, 176(2), 966–73.Google Scholar
  115. 115.
    Huang, M., Stolina, M., Sharma, S., et al. (1998). Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Research, 58(6), 1208–216.PubMedGoogle Scholar
  116. 116.
    Mitsuhashi, M., Liu, J., Cao, S., Shi, X., & Ma, X. (2004). Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. Journal of Leukocyte Biology, 76(2), 322–32.PubMedCrossRefGoogle Scholar
  117. 117.
    Snijdewint, F. G., Kalinski, P., Wierenga, E. A., Bos, J. D., & Kapsenberg, M. L. (1993). Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. Journal of Immunology, 150(12), 5321–329.Google Scholar
  118. 118.
    Uyttenhove, C., Pilotte, L., Theate, I., et al. (2003). Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine, 9(10), 1269–274.PubMedCrossRefGoogle Scholar
  119. 119.
    Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P., & Munn, D. H. (2002). Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. Journal of Immunology, 168(8), 3771–776.Google Scholar
  120. 120.
    Basu, G. D., Tinder, T. L., & Bradley, J. M., et al. (2006). Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: Role of IDO. Journal of Immunology, 177(4), 2391–402.Google Scholar
  121. 121.
    Mills, K. H. (2004). Regulatory T cells: Friend or foe in immunity to infection? Nature Reviews. Immunology, 4(11), 841–55.PubMedCrossRefGoogle Scholar
  122. 122.
    Baratelli, F., Lin, Y., Zhu, L., et al. (2005). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. Journal of Immunology, 175(3), 1483–490.Google Scholar
  123. 123.
    Claria, J., & Romano, M. (2005). Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Current Pharmaceutical Design, 11(26), 3431–447.PubMedCrossRefGoogle Scholar
  124. 124.
    Leone, S., Ottani, A., & Bertolini, A. (2007). Dual acting anti-inflammatory drugs. Current Topics in Medical Chemistry, 7(3), 265–75.CrossRefGoogle Scholar
  125. 125.
    Gilroy, D. W., Tomlinson, A., & Willoughby, D. A. (1998). Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. European Journal of Pharmacology, 355(2–), 211–17.PubMedCrossRefGoogle Scholar
  126. 126.
    Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A., & Serhan, C. N. (1987). Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science, 237(4819), 1171–176.PubMedCrossRefGoogle Scholar
  127. 127.
    Tager, A. M., Bromley, S. K., Medoff, B. D., et al. (2003). Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nature Immunology, 4(10), 982–90.PubMedCrossRefGoogle Scholar
  128. 128.
    Islam, S. A., Thomas, S. Y., Hess, C., et al. (2006). The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood, 107(2), 444–53.PubMedCrossRefGoogle Scholar
  129. 129.
    Taube, C., Miyahara, N., Ott, V., et al. (2006). The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. Journal of Immunology, 176(5), 3157–164.Google Scholar
  130. 130.
    Miyahara, N., Takeda, K., Miyahara, S., et al. (2005). Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine, 172(2), 161–67.PubMedCrossRefGoogle Scholar
  131. 131.
    Morita, H., Takeda, K., Yagita, H., & Okumura, K. (1999). Immunosuppressive effect of leukotriene B(4) receptor antagonist in vitro. Biochemical and Biophysical Research Communications, 264(2), 321–26.PubMedCrossRefGoogle Scholar
  132. 132.
    Yamaoka, K. A., Claesson, H. E., & Rosen, A. (1989). Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. Journal of Immunology, 143(6), 1996–000.Google Scholar
  133. 133.
    Gagnon, L., Girard, M., Sullivan, A. K., & Rola-Pleszczynski, M. (1987). Augmentation of human natural cytotoxic cell activity by leukotriene B4 mediated by enhanced effector-target cell binding and increased lytic efficiency. Cellular Immunology, 110(2), 243–52.PubMedCrossRefGoogle Scholar
  134. 134.
    Gualde, N., Cogny van Weydevelt, F., Buffiere, F., Jauberteau, M. O., Daculsi, R., & Vaillier, D. (1991). Influence of LTB4 on CD4-, CD8- thymocytes. Evidence that LTB4 plus IL-2 generate CD8+ suppressor thymocytes involved in tolerance to self. Effect of LTB4 and IL-2 on double negative thymocytes. Thymus, 18(2), 111–28.PubMedGoogle Scholar
  135. 135.
    Juzan, M., Guibert, F., & Gualde, N. (1998). Inhibition of graft-versus-host reaction by treatment of immature thymocytes with eicosanoids. Prostaglandins, Leukotrienes and Essential Fatty Acids, 58(1), 69–5.CrossRefGoogle Scholar
  136. 136.
    Robbiani, D. F., Finch, R. A., Jager, D., Muller, W. A., Sartorelli, A. C., & Randolph, G. J. (2000). The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell, 103(5), 757–8.PubMedCrossRefGoogle Scholar
  137. 137.
    Lamoureux, J., Stankova, J., & Rola-Pleszczynski, M. (2006). Leukotriene D4 enhances immunoglobulin production in CD40-activated human B lymphocytes. Journal of Allergy and Clinical Immunology, 117(4), 924–30.PubMedCrossRefGoogle Scholar
  138. 138.
    Prinz, I., Gregoire, C., Mollenkopf, H., et al. (2005). The type 1 cysteinyl leukotriene receptor triggers calcium influx and chemotaxis in mouse alpha beta- and gamma delta effector T cells. Journal of Immunology, 175(2), 713–19.Google Scholar
  139. 139.
    Wen, Y., Gu, J., Chakrabarti, S. K., et al. (2007). The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in macrophages. Endocrinology, 148(3), 1313–322.PubMedCrossRefGoogle Scholar
  140. 140.
    Aliberti, J., Hieny, S., Reis e Sousa, C., Serhan, C. N., & Sher, A. (2002). Lipoxin-mediated inhibition of IL-12 production by DCs: A mechanism for regulation of microbial immunity. Nature Immunology, 3(1), 76–2.PubMedCrossRefGoogle Scholar
  141. 141.
    Willson, T. M., Lehmann, J. M., & Kliewer, S. A. (1996). Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Annals of the New York Academy of Sciences, 804, 276–83.PubMedCrossRefGoogle Scholar
  142. 142.
    Appel, S., Mirakaj, V., Bringmann, A., Weck, M. M., Grunebach, F., & Brossart, P. (2005). PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood, 106(12), 3888–894.PubMedCrossRefGoogle Scholar
  143. 143.
    Yang, X. Y., Wang, L. H., Mihalic, K., et al. (2002). Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. Journal of Biological Chemistry, 277(6), 3973–978.PubMedCrossRefGoogle Scholar
  144. 144.
    Rioux, N., & Castonguay, A. (1998). Inhibitors of lipoxygenase: A new class of cancer chemopreventive agents. Carcinogenesis, 19(8), 1393–00.PubMedCrossRefGoogle Scholar
  145. 145.
    Ye, Y. N., Wu, W. K., Shin, V. Y., Bruce, I. C., Wong, B. C., & Cho, C. H. (2005). Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis, 26(4), 827–34.PubMedCrossRefGoogle Scholar
  146. 146.
    Hennig, R., Ding, X. Z., Tong, W. G., & Witt, R. C., Jovanovic, B. D., Adrian, T. E. (2004). Effect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Letters, 210(1), 41–6.PubMedCrossRefGoogle Scholar
  147. 147.
    Galfi, P., Neogrady, Z., Amberger, A., Margreiter, R., & Csordas, A. (2005). Sensitization of colon cancer cell lines to butyrate-mediated proliferation inhibition by combined application of indomethacin and nordihydroguaiaretic acid. Cancer Detection and Prevention, 29(3), 276–85.PubMedCrossRefGoogle Scholar
  148. 148.
    Anderson, K. M., Seed, T., & Vos, M., et al. (1998). 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate, 37(3), 161–73.PubMedCrossRefGoogle Scholar
  149. 149.
    Avis, I., Martinez, A., & Tauler, J., et al. (2005). Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Research, 65(10), 4181–190.PubMedCrossRefGoogle Scholar
  150. 150.
    Mayburd, A. L., Martlinez, A., & Sackett, D., et al. (2006). Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. Clinical Cancer Research, 12(6), 1820–827.PubMedCrossRefGoogle Scholar
  151. 151.
    Hazai, E., Bikadi, Z., Zsila, F., & Lockwood, S. F. (2006). Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyll, and selected oxidative metabolites with 5-lipoxygenase. Bioorganic and Medicinal Chemistry, 14(20), 6859–867.PubMedCrossRefGoogle Scholar
  152. 152.
    Bednar, W., Holzmann, K., & Marian, B. (2007). Assessing 12(S)-lipoxygenase inhibitory activity using colorectal cancer cells overexpressing the enzyme. Food and Chemical Toxicology, 45(3), 508–14.PubMedCrossRefGoogle Scholar
  153. 153.
    Tong, W. G., Ding, X. Z., Witt, R. C., & Adrian, T. E. (2002). Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Molecular Cancer Therapeutics, 1(11), 929–35.PubMedGoogle Scholar
  154. 154.
    Kuntz, S., Wenzel, U., & Daniel, H. (1999). Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. European Journal of Nutrition, 38(3), 133–42.PubMedCrossRefGoogle Scholar
  155. 155.
    Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., & Seeram, N. P., Shishodia, S., Takada, Y. (2004). Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. AntiCancer Research, 24(5A), 2783–840.PubMedGoogle Scholar
  156. 156.
    Ju, J., Liu, Y., Hong, J., Huang, M. T., Conney, A. H., & Yang, C. S. (2003). Effects of green tea and high-fat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethane-induced colon carcinogenesis mouse model. Nutrition and Cancer, 46(2), 172–78.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Graham P. Pidgeon
    • 1
    • 6
  • Joanne Lysaght
    • 2
  • Sriram Krishnamoorthy
    • 3
  • John V. Reynolds
    • 1
  • Ken O’Byrne
    • 4
  • Daotai Nie
    • 5
  • Kenneth V. Honn
    • 3
  1. 1.Department of Clinical SurgeryTrinity College Dublin, St. James HospitalDublin 8Ireland
  2. 2.Department of HaematologyTrinity College Dublin, St. James HospitalDublin 8Ireland
  3. 3.Department of PathologyWayne State University School of Medicine & Karmanos Cancer InstituteDetroitUSA
  4. 4.Department of Clinical MedicineTrinity College Dublin, St. James HospitalDublin 8Ireland
  5. 5.Department of Medical Microbiology, Immunology, and Cell BiologySouthern Illinois University School of Medicine and Cancer InstituteSpringfieldUSA
  6. 6.Department of Clinical Surgery, Institute of Molecular MedicineTrinity Center for Health Sciences, TCD/St. James’s HospitalDublin 8Ireland

Personalised recommendations